Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

被引：1
|
作者：
McCaughan, Georgia J. [1 ,2 ]
Verma, Anvita [2 ,3 ]
Ling, Silvia [2 ,3 ]
Lavee, Orly [1 ]
Moore, John J. [1 ,3 ]
Bryant, Adam [2 ,3 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[3] Liverpool Hosp, Dept Haematol, Sydney, NSW, Australia
来源：
BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / 03期
关键词：
INDUCTION THERAPY; DEXAMETHASONE VCD; SUPERIOR; VTD;
D O I：
10.1038/s41409-020-01086-9
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：738 / 740
页数：3
相关论文
共 50 条
  • [1] Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres
    Georgia J. McCaughan
    Anvita Verma
    Silvia Ling
    Orly Lavee
    John J. Moore
    Adam Bryant
    Bone Marrow Transplantation, 2021, 56 : 738 - 740
  • [2] Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres
    McCaughan, Georgia J.
    Verma, Anvita
    Ling, Silvia
    Lavee, Orly
    Moore, John
    Bryant, Adam
    BLOOD, 2020, 136
  • [3] Initial treatment of transplant-eligible patients in multiple myeloma
    Rosinol, Laura
    Kumar, Shaji
    Moreau, Phillipe
    Cavo, Michele
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 43 - 53
  • [4] Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [5] Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014
    Landau, Heather
    Giralt, Sergio
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (05) : 815 - +
  • [6] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor
    Bahlis, Nizar J.
    Duggan, Peter
    Alonso, Rafael
    Lahuerta, Juan Jose
    Valeri, Antonio
    Neri, Paola
    Tay, Jason
    Martinez-Lopez, Joaquin
    BLOOD, 2016, 128 (22)
  • [7] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Venner, Christopher P.
    Belch, Andrew
    Sandhu, Irwindeep
    Nikitina, Tatiana
    Hewitt, Joanne D.
    Duggan, Peter
    Neri, Paola
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    BLOOD, 2015, 126 (23)
  • [8] TREATMENT WITH CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) OF PATIENTE WITH MULTIPLE MYELOMA CANDIDATES TO HEMATOPOIETIC TRANSPLANT
    Capote Huelva, F. J.
    Moran Sanchez, J.
    Capote Garcia, J.
    Martin Reina, M., V
    Fernandez Valle, M. C.
    Marchante Cepillo, I
    Paz Coll, A.
    HAEMATOLOGICA, 2015, 100 : 244 - 244
  • [9] Induction Treatment in Transplant-eligible Multiple Myeloma
    Quinn, J.
    Glavey, S.
    Comerford, C.
    Murphy, P.
    HEMASPHERE, 2021, 5 (05):
  • [10] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
    Nakaseko, Chiaki
    ANNALS OF ONCOLOGY, 2017, 28
12345